The medical community has officially reclassified polycystic ovary syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS). Announced at the European Congress of Endocrinology in Prague and published in The Lancet, this change reflects a fundamental shift in understanding the condition as a complex, lifelong hormonal and metabolic disorder rather than solely a reproductive issue.
Dr. Veronique Viardot-Foucault of KK Women’s and Children’s Hospital noted that the previous terminology was misleading, as many patients do not have ovarian cysts. The term PMOS acknowledges the involvement of multiple hormone systems, including insulin regulation and brain-hormone signaling, which impact metabolism, skin health, and mental well-being.
The renaming aims to reduce the stigma associated with infertility and redirect clinical focus toward chronic disease management. Dr. Clara Ong of Parkway MediCentre emphasized that 'polyendocrine' recognizes systemic hormonal imbalances, while 'metabolic' highlights core risks such as insulin resistance, diabetes, and cardiovascular issues.
Diagnosis criteria remain unchanged, requiring two of three indicators: irregular periods, elevated androgen levels or related symptoms like hirsutism, and ultrasound evidence of ovarian morphology or elevated anti-mullerian hormone. However, the clinical approach is evolving. Experts advocate for a multidisciplinary strategy involving endocrinologists, dietitians, and mental health professionals to address the full spectrum of symptoms.
Insulin resistance affects up to 70 percent of women with PMOS, increasing the risk of type 2 diabetes and heart disease. This risk persists even in lean patients, necessitating regular metabolic screening beyond weight-based assumptions.
The historical focus on cysts and fertility led to significant diagnostic delays, with nearly half of patients seeing multiple specialists before receiving a correct diagnosis. The new nomenclature empowers clinicians to treat PMOS as an interconnected system of hormonal and metabolic health, potentially reducing missed diagnoses and improving long-term patient outcomes.
